S&P 500

5.304,72

0,70%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Inhibrx Inc (INBX)
Inhibrx Inc (INBX) Notícias

INBX

Inhibrx (INBX)

Inhibrx Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:INBX

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
24/05/2024	19:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INBX	Inhibrx Inc
24/05/2024	17:44	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:INBX	Inhibrx Inc
24/05/2024	17:08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INBX	Inhibrx Inc
24/05/2024	17:00	PR Newswire (US)	Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi	NASDAQ:INBX	Inhibrx Inc
22/05/2024	10:54	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:INBX	Inhibrx Inc
20/05/2024	22:48	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:INBX	Inhibrx Inc
10/05/2024	19:36	PR Newswire (US)	Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off	NASDAQ:INBX	Inhibrx Inc
08/05/2024	17:37	PR Newswire (US)	Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger	NASDAQ:INBX	Inhibrx Inc
29/02/2024	19:26	Edgar (US Regulatory)	Form PREM14A - Preliminary proxy statements relating to merger or acquisition	NASDAQ:INBX	Inhibrx Inc
28/02/2024	11:15	PR Newswire (US)	Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results	NASDAQ:INBX	Inhibrx Inc
28/02/2024	11:10	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:INBX	Inhibrx Inc
14/02/2024	18:12	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:INBX	Inhibrx Inc
26/01/2024	14:12	PR Newswire (US)	Kuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law Firm	NASDAQ:INBX	Inhibrx Inc
23/01/2024	08:05	Dow Jones News	Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update	NASDAQ:INBX	Inhibrx Inc
23/01/2024	07:40	IH Market News	Wall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and More	NASDAQ:INBX	Inhibrx Inc
23/01/2024	03:00	PR Newswire (US)	Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B	NASDAQ:INBX	Inhibrx Inc
09/11/2023	18:01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:INBX	Inhibrx Inc
09/11/2023	18:00	PR Newswire (US)	Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights	NASDAQ:INBX	Inhibrx Inc
02/11/2023	10:15	PR Newswire (US)	Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma	NASDAQ:INBX	Inhibrx Inc
18/10/2023	17:00	PR Newswire (US)	Inhibrx Announces Participation in Upcoming Scientific Conferences	NASDAQ:INBX	Inhibrx Inc
19/09/2023	17:00	PR Newswire (US)	Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada	NASDAQ:INBX	Inhibrx Inc
31/08/2023	17:06	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:INBX	Inhibrx Inc
29/08/2023	10:00	PR Newswire (US)	Inhibrx Announces $200 Million Private Placement Financing	NASDAQ:INBX	Inhibrx Inc
07/08/2023	17:00	PR Newswire (US)	Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights	NASDAQ:INBX	Inhibrx Inc
30/05/2023	17:11	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:INBX	Inhibrx Inc
30/05/2023	10:46	Dow Jones News	Inhibrx Granted FDA Fast Track Designation for INBRX-101	NASDAQ:INBX	Inhibrx Inc
30/05/2023	10:04	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:INBX	Inhibrx Inc
30/05/2023	10:00	PR Newswire (US)	Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency	NASDAQ:INBX	Inhibrx Inc
08/05/2023	17:05	PR Newswire (US)	Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights	NASDAQ:INBX	Inhibrx Inc
08/05/2023	17:03	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:INBX	Inhibrx Inc